The current market turmoil offers a great opportunity to snap up the shares ofHSBC (LSE: HSBC), SABMiller (LSE: SAB), and GlaxoSmithKline (LSE: GSK). Lets check out their recent performances and a few other financial metrics.
HSBC: Time To Buy?
The bank is selling assets to shore up its capital position, but the market is concerned about sluggish growth in Asia, where a large portion of its operations are based.
Its shares currently change hands at around 500p and are down 20% in 2015; according to consensus estimates from Thomson Reuters, they offer upside of about 20%, but if bullish analysts are right, capital gains could be in the region of 50% over the next 12months.
I am inclined to agree with those projections, and not only because HSBC stock trades atdepressed trading multiples of 10x forwardearnings. Its payout ratio is fine, while its high dividend yield (6.4%)signals that the shares may be oversold as investors overreacted to very bad news from China in recent weeks.
SABMiller:A Solid Buy At This Price?
This is a slightly less risky investment than HSBC, at least based on its beta of 1 versus HSBCs 1.1.
The brewer is a long-term bet on emerging market growth, but even if growth sputters there, it remains an appealing proposition at its current share price of 2,960p. I have long argued that its fair value is around 3,200p, so if I am right and if you buy its shares today! you could pocket an immediate 8% pre-tax paper gain.
Its equity valuationhas fallen 10% year to date but has come under more pressurein recent days as Citigroup and Credit Suisse downgraded the stock to 3,300p and 3,100p, respectively.While its true that large acquisitions will be difficult to pull off following the $10bn+ purchase of Fosters in 2011 (hence SAB now offers less synergy potential than in previous years), SAB management has historically been particularly good at targeting efficiency measures, while receiving the backing of relationship banks, which has helped itmanage effectively its capitalbase.
All this will likely support a dividend yield of between 2.5% and 3% over the next 30 months.
With a lowlybeta of 0.6, GSK should bethe less risky investment of the three in a bear market, but I have doubts that management will be able to meet expectations.Theres no sign of much-needed spin-offs, which were expected towards the end of the year.
After a decent start in 2015, management has failed to convince investors that they should pay up to own Glaxo stock: one problem is that managers have proved to be too conservative, although Glaxo has clearly outperformed both SAB and HSBC, having recorded a -6% performance since early January.
According to market consensus estimates from Thomson Reuters, potential upside here is lower than that of HSBC and SAB at between 11% and 34%. My take is that based on a multitude of factors trading multiples, assets base, returns cycle, drugs pipeline its shares may have only one way to go, and that is up!
Glaxo is one of afew growth stocks that promise significant income from dividendsover the long run. But if you want to learn more about other opportunities, you are in the right place!
We have identified many value shares that promise even greater capital appreciation: I suggest you spend timedelving into an exclusive value reportfrom ourteam of Motley Foolanalysts,which confirms that this is agood time to pick up stocks that could deliver market-beating performances.
Get yourfree copy, but click here right away—our report isavailable only for a limited amount of time!